The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea.
To investigate the efficiency of Saccharomyces boulardii on irinotecan-induced mucosal damage and diarrhea in rats, fifty rats were randomized into three groups with 20 rats in two study groups and 10 rats in the control group. Control group did not receive any treatment. Irinotecan (60 mg/kg) alone was administered intravenously once a day for four consecutive days to the rats of Group A. Throughout the experiment, Group B rats were additionally given Saccharomyces boulardii (800 mg/kg) for 3 days before administration of irinotecan and 7 days throughout the experiment. Delayed diarrhea was more severe in Group A than Group B (P = 0.009). The weight loss was 34.7 +/- 3.8 mg for Group A, while it was 17.4 +/- 1.7 mg for Group B (P < 0.001). Findings of mucositis most clearly appeared in the jejunum. Regarding edema (P = 0.003), leukocyte migration (P = 0.038), and inflammation (P = 0.006) significant recovery was detected in the mucosa of rats receiving Saccharomyces boulardii. Villous thickness was significantly greater in Group A than Group B (P < 0.001). The results indicate that Saccharomyces boulardii provided significant improvement in irinotecan-induced diarrhea and mucositis.
Sezer
Atakan
A
Department of General Surgery, Faculty of Medicine, Trakya University, Edirne, Turkey.
Usta
Ufuk
U
Cicin
Irfan
I
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000633:toxicity*; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000633:toxicity; D003967:Diarrhea / Q000139:chemically induced / Q000628:therapy*; D006651:Histocytochemistry; D000077146:Irinotecan; D007962:Leukocytes / Q000473:pathology; D052016:Mucositis / Q000139:chemically induced / Q000382:microbiology / Q000473:pathology / Q000628:therapy*; D051381:Rats; D012440:Saccharomyces; D015431:Weight Loss
D000972:Antineoplastic Agents, Phytogenic; D000077146:Irinotecan; D002166:Camptothecin